Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glucose-based peritoneal dialysate is a sterile solution used in peritoneal dialysis for patients with kidney failure. The primary osmotic agent in this fluid is glucose, which draws waste products and excess water from the blood across the peritoneum into the abdominal cavity. After a dwell period, the fluid containing waste is drained and discarded. Glucose remains the standard osmotic agent due to its low cost and metabolic efficiency; however, chronic exposure to high-glucose solutions can lead to adverse metabolic effects such as hyperglycemia, insulin resistance, dyslipidemia, hypertension, overweight/obesity, and increased cardiovascular risk. Prolonged use may also cause local complications including peritoneal fibrosis and angiogenesis[2][4][6]. Glucose absorption from these solutions contributes significantly to caloric load in patients on long-term therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucose-based peritoneal dialysate.